112 related articles for article (PubMed ID: 26044202)
1. The effect of AZD2171- or sTRAIL/Apo2L-loaded polylactic-co-glycolic acid microspheres on a subcutaneous glioblastoma model.
Shivinsky A; Bronshtein T; Haber T; Machluf M
Biomed Microdevices; 2015 Aug; 17(4):69. PubMed ID: 26044202
[TBL] [Abstract][Full Text] [Related]
2. Continuous delivery of endogenous inhibitors from poly(lactic-co-glycolic acid) polymeric microspheres inhibits glioma tumor growth.
Benny O; Duvshani-Eshet M; Cargioli T; Bello L; Bikfalvi A; Carroll RS; Machluf M
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):768-76. PubMed ID: 15701867
[TBL] [Abstract][Full Text] [Related]
3. A sulfate polysaccharide/TNF-related apoptosis-inducing ligand (TRAIL) complex for the long-term delivery of TRAIL in poly(lactic-co-glycolic acid) (PLGA) microspheres.
Kim H; Jeong D; Kang HE; Lee KC; Na K
J Pharm Pharmacol; 2013 Jan; 65(1):11-21. PubMed ID: 23215683
[TBL] [Abstract][Full Text] [Related]
4. Controlled release microspheres loaded with BMP7 suppress primary tumors from human glioblastoma.
González-Gómez P; Crecente-Campo J; Zahonero C; de la Fuente M; Hernández-Laín A; Mira H; Sánchez-Gómez P; Garcia-Fuentes M
Oncotarget; 2015 May; 6(13):10950-63. PubMed ID: 25860932
[TBL] [Abstract][Full Text] [Related]
5. Local delivery of poly lactic-co-glycolic acid microspheres containing imatinib mesylate inhibits intracranial xenograft glioma growth.
Benny O; Menon LG; Ariel G; Goren E; Kim SK; Stewman C; Black PM; Carroll RS; Machluf M
Clin Cancer Res; 2009 Feb; 15(4):1222-31. PubMed ID: 19190128
[TBL] [Abstract][Full Text] [Related]
6. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.
Maris JM; Courtright J; Houghton PJ; Morton CL; Gorlick R; Kolb EA; Lock R; Tajbakhsh M; Reynolds CP; Keir ST; Wu J; Smith MA
Pediatr Blood Cancer; 2008 Mar; 50(3):581-7. PubMed ID: 17457854
[TBL] [Abstract][Full Text] [Related]
7. Verteporfin-Loaded Polymeric Microparticles for Intratumoral Treatment of Brain Cancer.
Shah SR; Kim J; Schiapparelli P; Vazquez-Ramos CA; Martinez-Gutierrez JC; Ruiz-Valls A; Inman K; Shamul JG; Green JJ; Quinones-Hinojosa A
Mol Pharm; 2019 Apr; 16(4):1433-1443. PubMed ID: 30803231
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.
Cao C; Albert JM; Geng L; Ivy PS; Sandler A; Johnson DH; Lu B
Cancer Res; 2006 Dec; 66(23):11409-15. PubMed ID: 17145887
[TBL] [Abstract][Full Text] [Related]
9. In vivo fate and therapeutic efficacy of PF-4/CTF microspheres in an orthotopic human glioblastoma model.
Benny O; Kim SK; Gvili K; Radzishevsky IS; Mor A; Verduzco L; Menon LG; Black PM; Machluf M; Carroll RS
FASEB J; 2008 Feb; 22(2):488-99. PubMed ID: 17873103
[TBL] [Abstract][Full Text] [Related]
10. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
Wedge SR; Kendrew J; Hennequin LF; Valentine PJ; Barry ST; Brave SR; Smith NR; James NH; Dukes M; Curwen JO; Chester R; Jackson JA; Boffey SJ; Kilburn LL; Barnett S; Richmond GH; Wadsworth PF; Walker M; Bigley AL; Taylor ST; Cooper L; Beck S; Jürgensmeier JM; Ogilvie DJ
Cancer Res; 2005 May; 65(10):4389-400. PubMed ID: 15899831
[TBL] [Abstract][Full Text] [Related]
11. PEGylated TNF-related apoptosis-inducing ligand (TRAIL)-loaded sustained release PLGA microspheres for enhanced stability and antitumor activity.
Kim TH; Jiang HH; Park CW; Youn YS; Lee S; Chen X; Lee KC
J Control Release; 2011 Feb; 150(1):63-9. PubMed ID: 21062635
[TBL] [Abstract][Full Text] [Related]
12. The characterization of paclitaxel-loaded microspheres manufactured from blends of poly(lactic-co-glycolic acid) (PLGA) and low molecular weight diblock copolymers.
Jackson JK; Hung T; Letchford K; Burt HM
Int J Pharm; 2007 Sep; 342(1-2):6-17. PubMed ID: 17555895
[TBL] [Abstract][Full Text] [Related]
13. Local antitumor effects of intratumoral delivery of rlL-2 loaded sustained-release dextran/PLGA-PLA core/shell microspheres.
Zhao H; Wu F; Cai Y; Chen Y; Wei L; Liu Z; Yuan W
Int J Pharm; 2013 Jun; 450(1-2):235-40. PubMed ID: 23624084
[TBL] [Abstract][Full Text] [Related]
14. The angiogenic effect of ONO-1301, a novel long-acting prostacyclin agonist loaded in PLGA microspheres prepared using different molecular weights of PLGA, in a murine sponge model.
Hazekawa M; Morihata K; Yoshida M; Sakai Y; Uchida T
Drug Dev Ind Pharm; 2014 Nov; 40(11):1435-42. PubMed ID: 23937583
[TBL] [Abstract][Full Text] [Related]
15. Release mechanisms of tacrolimus-loaded PLGA and PLA microspheres and immunosuppressive effects of the microspheres in a rat heart transplantation model.
Kojima R; Yoshida T; Tasaki H; Umejima H; Maeda M; Higashi Y; Watanabe S; Oku N
Int J Pharm; 2015 Aug; 492(1-2):20-7. PubMed ID: 26160668
[TBL] [Abstract][Full Text] [Related]
16. The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model.
Gomez-Rivera F; Santillan-Gomez AA; Younes MN; Kim S; Fooshee D; Zhao M; Jasser SA; Myers JN
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4519-27. PubMed ID: 17671138
[TBL] [Abstract][Full Text] [Related]
17. A novel sustained-release formulation of recombinant human growth hormone and its pharmacokinetic, pharmacodynamic and safety profiles.
Wei Y; Wang Y; Kang A; Wang W; Ho SV; Gao J; Ma G; Su Z
Mol Pharm; 2012 Jul; 9(7):2039-48. PubMed ID: 22663348
[TBL] [Abstract][Full Text] [Related]
18. Prevention of local tumor growth with paclitaxel-loaded microspheres.
Azouz SM; Walpole J; Amirifeli S; Taylor KN; Grinstaff MW; Colson YL
J Thorac Cardiovasc Surg; 2008 May; 135(5):1014-21. PubMed ID: 18455578
[TBL] [Abstract][Full Text] [Related]
19. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor.
Takeda M; Arao T; Yokote H; Komatsu T; Yanagihara K; Sasaki H; Yamada Y; Tamura T; Fukuoka K; Kimura H; Saijo N; Nishio K
Clin Cancer Res; 2007 May; 13(10):3051-7. PubMed ID: 17505008
[TBL] [Abstract][Full Text] [Related]
20. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
Pollack IF; Erff M; Ashkenazi A
Clin Cancer Res; 2001 May; 7(5):1362-9. PubMed ID: 11350907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
